ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2887

Clinical Predictors for Development of Interstitial Lung Disease in Mixed Connective Tissue Disease

Neha Narula1, Tathagat Narula2, Benjamin Wang1 and Andy Abril1, 1Division of Rheumatology, Mayo Clinic, Jacksonville, FL, 2Pulmonary and critical care medicine, Respiratory Critical Care & Sleep Medicine Associates, Jacksonville, FL

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Interstitial lung disease and mixed connective tissue disease (MCTD)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Mixed connective tissue disease (MCTD) is an immune-mediated systemic disorder characterized by serum autoantibodies against U1-ribonucleoprotein and diverse multisystemic clinical manifestations. Approximately 50% of patients with MCTD develop a radiological pattern of interstitial lung disease (ILD). In this study, we explore the phenotypic and clinical features in patients with MCTD that are associated with development of ILD.

Methods: We performed a retrospective case control study utilizing data from patients evaluated at a single tertiary care center from 2007-2014. Twenty-eight patients who met validated criteria for diagnosis of MCTD were included in the study. Fourteen patients had high-resolution computed tomography or biopsy-proven ILD, and 14 had MCTD without evidence of ILD . We performed a multivariate logistic regression with multiple demographic, clinical, and serologic predictor variables, and ILD as the outcome variable.

Results:  Two clinical variables had an association with development of ILD in patients with MCTD:

  1. Dysphagia with a R2 value of 0.33 (p value < 0.001)
  2. Raynaud’s phenomenon with R2 value of 0.28 (p value < 0.001)

 We did not find a significant association between any other demographic, clinical, or serologic variables and development of ILD in patients with MCTD.

Conclusion: Dysphagia is one of the symptoms of esophageal involvement in patients with autoimmune connective tissue disorders. An association of dysphagia with the development of ILD in our study is in harmony with the existing literature, wherein esophageal dysmotility has been described in a cluster of patients with MCTD and ILD. Scant data, primarily case reports, suggest an association of Raynaud’s phenomenon with development of ILD in patients with undifferentiated CTD. To our knowledge, this is the first study highlighting the association of Raynaud’s phenomenon with development of ILD in patients with MCTD.   This study is limited by its small size and retrospective nature. The mechanistic aspects of the association between Raynaud’s phenomenon and ILD remain unexplored. The association of easily elicited historical and clinical features of MCTD with subtle, but worrisome, pulmonary pathology carries the promise of sensitizing the unsuspecting clinician about the entity of ILD in MCTD.


Disclosure: N. Narula, None; T. Narula, None; B. Wang, None; A. Abril, None.

To cite this abstract in AMA style:

Narula N, Narula T, Wang B, Abril A. Clinical Predictors for Development of Interstitial Lung Disease in Mixed Connective Tissue Disease [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/clinical-predictors-for-development-of-interstitial-lung-disease-in-mixed-connective-tissue-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-predictors-for-development-of-interstitial-lung-disease-in-mixed-connective-tissue-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology